GSK collaborates with Lyell Immunopharma on cancer cell therapies Medical Dialogues Bureau12 Oct 2019 9:15 AM ISTCombining GSK plc's strong cell and gene therapy programmes with Lyell's technologies may allow the joint research team to maximize the activity and...
Novartis, Gilead costly cancer therapies Yescarta, Kymriah losing patients to experimental treatments Medical Dialogues Bureau3 Aug 2019 9:15 AM ISTBoth Gilead's Yescarta and Novartis's Kymriah - which are part of a class of therapies known in the medical field as "CAR-T" - were approved in 2017....
Novartis Kymriah wins UK backing after initial lymphoma snub Medical Dialogues Bureau3 Feb 2019 10:00 AM IST"Today's positive announcement regarding access to Kymriah treatment in England and Wales was secured as a result of our close working collaboration...
Gilead Sciences new drug keeps 56 percent of lymphoma trial patients alive Ruby Khatun Khatun11 Dec 2017 10:30 AM ISTMore than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a...
